Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 12;9(8):427.
doi: 10.3390/vetsci9080427.

Survival Time after Surgical Debulking and Temozolomide Adjuvant Chemotherapy in Canine Intracranial Gliomas

Emma Hidalgo Crespo  1 , Alba Farré Mariné  1 , Martí Pumarola I Battle  2 , Juan Francisco Borrego Massó  1 , Alejandro Luján Feliu-Pascual  1
Affiliations

Survival Time after Surgical Debulking and Temozolomide Adjuvant Chemotherapy in Canine Intracranial Gliomas

Emma Hidalgo Crespo et al. Vet Sci. .

Abstract

Intracranial gliomas are associated with a poor prognosis, and the most appropriate treatment is yet to be defined. The objectives of this retrospective study are to report the time to progression and survival times of a group of dogs with histologically confirmed intracranial gliomas treated with surgical debulking and adjuvant temozolomide chemotherapy. All cases treated in a single referral veterinary hospital from 2014 to 2021 were reviewed. Inclusion criteria comprised a histopathological diagnosis of intracranial glioma, adjunctive chemotherapy, and follow-up until death. Cases were excluded if the owner declined chemotherapy or there was insufficient follow-up information in the clinical records. Fourteen client-owned dogs were included with a median time to progression (MTP) of 156 days (95% CI 133-320 days) and median survival time (MST) of 240 days (95% CI 149-465 days). Temozolomide was the first-line adjuvant chemotherapy but changed to another chemotherapy agent (lomustine, toceranib phosphate, or melphalan) when tumour relapse was either suspected by clinical signs or confirmed by advanced imaging. Of the fourteen dogs, three underwent two surgical resections and one, three surgeries. Survival times (ST) were 241, 428, and 468 days for three dogs treated twice surgically and 780 days for the dog treated surgically three times. Survival times for dogs operated once was 181 days. One case was euthanized after developing aspiration pneumonia, and all other cases after progression of clinical signs due to suspected or confirmed tumour relapse. In conclusion, the results of this study suggest that debulking surgery and adjuvant chemotherapy are well-tolerated options in dogs with intracranial gliomas in which surgery is a possibility and should be considered a potential treatment option. Repeated surgery may be considered for selected cases.

Keywords: chemotherapy; glioma; intracranial tumour; surgery; survival time; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Transverse pre (A) and post (B) contrast CT brain image with soft tissue algorithm. The images reveal an intra-axial, ill-defined round, hypoattenuating lesion located in the left frontal lobe of the cerebrum. The lesion shows ring enhancement after ionated contrast administration and a slight midline shift to the right. Histopathological diagnosis was oligodendroglioma grade II.
Figure 2
Figure 2
Kaplan-Meier median time to progression (MTP) curve of all dogs.
Figure 3
Figure 3
Kaplan-Meier median survival time (MST) curve of all dogs. The only censored patient is marked.
See this image and copyright information in PMC

References

    1. Song R., Vite C., Bradley C., Cross J. Postmortem Evaluation of 435 Cases of Intracranial Neoplasia in Dogs and Relationship of Neoplasm with Breed, Age, and Body Weight. J. Veter- Intern. Med. 2013;27:1143–1152. doi: 10.1111/jvim.12136. - DOI - PubMed
    1. José-López R., Gutierrez-Quintana R., de la Fuente C., Manzanilla E.G., Suñol A., Castro D.P., Añor S., Sánchez-Masian D., Fernández-Flores F., Ricci E., et al. Clinical features, diagnosis, and survival analysis of dogs with glioma. J. Veter- Intern. Med. 2021;35:1902–1917. doi: 10.1111/jvim.16199. - DOI - PMC - PubMed
    1. Dickinson P. Advances in Diagnostic and Treatment Modalities for Intracranial Tumors. J. Veter- Intern. Med. 2014;28:1165–1185. doi: 10.1111/jvim.12370. - DOI - PMC - PubMed
    1. McGrath J.T. Intracranial Pathology of the Dog. Acta Neuropathol. 1962:3–4. doi: 10.1007/978-3-642-92847-5_2. - DOI
    1. Snyder J.M., Shofer F.S., Winkle T.J., Massicotte C. Canine Intracranial Primary Neoplasia: 173 Cases (1986–2003) J. Veter- Intern. Med. 2006;20:669–675. doi: 10.1111/j.1939-1676.2006.tb02913.x. - DOI - PubMed

LinkOut - more resources